ProfileGDS5678 / 1443998_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 67% 67% 74% 65% 70% 68% 67% 72% 66% 68% 69% 67% 67% 67% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.0691167
GSM967853U87-EV human glioblastoma xenograft - Control 24.0812967
GSM967854U87-EV human glioblastoma xenograft - Control 34.8798674
GSM967855U87-EV human glioblastoma xenograft - Control 43.9378165
GSM967856U87-EV human glioblastoma xenograft - Control 54.316670
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.1720868
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.1508867
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.5519572
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.9656966
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.1390468
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.2058369
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.0587967
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.0501767
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.0479967